Advate vs Ultomiris
Side-by-side cost comparison based on Medicare Part D data
Advate
Antihemophilic Factor (rDNA)
Manufactured by Takeda
Ultomiris
Ravulizumab
Manufactured by Alexion
Advate costs 61% less per claim than Ultomiris ($25,333.00 vs $65,292.00). A generic version of Advate is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Advate | Ultomiris |
|---|---|---|
| Avg Cost Per Claim | $25,333.00 | $65,292.00 |
| Total Medicare Spending | $456.0M | $1.6B |
| Total Beneficiaries | 2,100 | 4,800 |
| Total Claims | 18,000 | 24,000 |
| Annual Cost/Patient | $217,143.00 | $326,458.00 |
| Year-over-Year Change | -14.6% | +32.4% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Takeda | Alexion |
| Condition | Blood Disorders | Blood Disorders |
| Generic Name | Antihemophilic Factor (rDNA) | Ravulizumab |
Advate vs Ultomiris: What the Data Shows
Advate (Antihemophilic Factor (rDNA)) and Ultomiris (Ravulizumab) are both used to treat blood disorders. Based on Medicare Part D data, Advate costs $25,333.00 per claim, which is 61% less than Ultomiris at $65,292.00 per claim.
Medicare spent $456.0M on Advate and $1.6B on Ultomiris. In terms of patient reach, Ultomiris serves more beneficiaries (4,800 vs 2,100).
Year-over-year spending changed -14.6% for Advate and +32.4% for Ultomiris. Ultomiris saw significant spending growth, suggesting increased utilization or price increases.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Advate is cheaper at $25,333.00 per claim, compared to $65,292.00 for Ultomiris. That makes Advate about 61% less expensive per claim based on Medicare Part D data.
Yes, both Advate and Ultomiris are used to treat blood disorders. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Antihemophilic Factor (rDNA) and generic Ravulizumab can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $456.0M on Advate covering 2,100 beneficiaries, and $1.6B on Ultomiris covering 4,800 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.